Crossmark

Early shift to oral antibiotic treatment for pyogenic vertebral osteomyelitis (SAVE): study protocol for an open label, non-inferiority, nation-wide randomized controlled clinical trial

Crossref DOI link: https://doi.org/10.1186/s13063-025-09316-5

Published Online: 2025-12-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Theilgaard, Zahra Persson https://orcid.org/0009-0001-9217-3632
Weis, Nina

Ravn, Pernille

Bernhard, Peter Haahr

Jørgensen, Nis Pedersen

Knudsen, Jesper Andreas

Öbrink-Hansen, Kristina

Ørsted, Iben

Schønning, Kristian

Johansen, Isik Somuncu

Lebech, Anne-Mette
Funding

Funding for this research was provided by:

Novo Nordisk Fonden (NNF22OC0078062)

Sygeforsikringen "danmark" (2022-0225)

Region Hovedstaden

Copenhagen University
License Information

Text and Data Mining valid from 2025-12-10

Version of Record valid from 2026-01-13
More Information

Article History

Received: 10 April 2025

Accepted: 17 November 2025

First Online: 10 December 2025

Declarations

:

: The study has received approval from the Danish Medical Research Ethics Committees and the Danish Medicines Agency. Date of approval 27-11-2023, reference number EU CT Nr 2023–507617-96-01. Written, informed consent to participate will be obtained from all study participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below